Inhibition-mediating dopamine receptors and the control of intracranial reward.
A receptor selective agonist and antagonist of inhibition-mediating dopamine receptors (type II receptors) produced significant and dose-related alterations in bar-pressing for intracranial reward. Receptor inhibition by piribedil increased responding for reward while receptor activation by 3,4-dihydroxyphenylamino-2-imidazoline reduced responding. Inhibition-mediating receptors may therefore play a role opposite to classic excitation-mediating receptors in controlling reward.
D000818:Animals; D001921:Brain / Q000502:physiology*; D003891:Desipramine / Q000494:pharmacology; D004558:Electric Stimulation; D007093:Imidazoles / Q000494:pharmacology; D008297:Male; D010891:Piribedil / Q000494:pharmacology; D051381:Rats; D011954:Receptors, Dopamine / Q000502:physiology*; D012201:Reward; D012653:Self Stimulation / Q000187:drug effects; D013997:Time Factors
D007093:Imidazoles; D011954:Receptors, Dopamine; D010891:Piribedil; D003891:Desipramine